펩티드 및 헤파린 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 용도별, 투여 경로별, 최종 사용자별, 지역별 및 경쟁(2021-2031년)

The global market for peptides and heparin is projected to expand significantly, rising from USD 13.41 billion in 2025 to USD 21.72 billion by 2031, reflecting an 8.37% compound annual growth rate. Peptides, defined as short chains of amino acids, regulate specific biological activities, while heparin is a crucial sulfated glycosaminoglycan serving as an anticoagulant. This growth is predominantly fueled by the increasing worldwide incidence of chronic metabolic and cardiovascular diseases, which demand continuous therapeutic solutions. For instance, the International Diabetes Federation estimated that 589 million adults would be living with diabetes globally in 2025, directly boosting the need for peptide-based treatments. Technological progress in chemical synthesis has also enhanced the stability and bioavailability of these therapeutics, broadening their clinical utility. However, market expansion faces a substantial hurdle in the form of a fragile supply chain, particularly for heparin's raw materials. The heavy reliance on porcine intestinal mucosa renders production vulnerable to disruptions from livestock diseases and contamination, creating potential manufacturing bottlenecks and supply shortages that could restrict the availability and distribution of these essential medications.

Market Driver

The escalating prevalence of cardiovascular and metabolic diseases serves as a primary driver for the peptides and heparin market. The success of Glucagon-like Peptide-1 (GLP-1) receptor agonists, which are peptide-based biologics offering effective glycemic control and weight reduction, has particularly spurred growth in the peptide sector, requiring expanded manufacturing. Novo Nordisk's financial report for 2024 showed a 25% increase in Diabetes and Obesity care sales, largely due to GLP-1 demand, underscoring peptides' vital role in managing metabolic conditions. Concurrently, the rising occurrence of coagulation disorders and thromboembolic events sustains the demand for heparin as an essential anticoagulant, especially in critical care. The International Society on Thrombosis and Haemostasis highlighted in October 2024 that one in four global deaths are linked to thrombosis-related conditions, emphasizing this continuous need. Furthermore, regulatory support for innovation is robust, with peptide and nucleic acid-based therapies accounting for roughly 10% of new FDA drug approvals in recent years, according to BioSpace in January 2025, signaling a strong pipeline.

Market Challenge

The primary impediment to the global peptides and heparin market's growth is the unstable supply chain, specifically its heavy dependence on porcine intestinal mucosa for heparin production. Since heparin almost exclusively uses animal-derived raw materials, the industry is highly susceptible to volatility caused by livestock diseases and trade disruptions. Outbreaks of such diseases immediately reduce the availability of healthy porcine mucosa, creating bottlenecks in Active Pharmaceutical Ingredient (API) manufacturing. This scarcity elevates procurement costs and limits the volume of finished drugs, thereby capping market expansion despite rising patient needs. Consequently, manufacturers struggle to maintain consistent inventory, leading to supply instability that hinders both revenue generation and reliable drug distribution. These interruptions prevent the market from fully capitalizing on the increasing prevalence of cardiovascular conditions. The severity of these supply issues is evident in figures from the American Society of Health-System Pharmacists, which reported 214 active drug shortages in Q3 2025, with heparin remaining a persistently difficult sterile injectable to source due to ongoing raw material and manufacturing vulnerabilities.

Market Trends

The market is undergoing a significant transformation with the shift towards oral peptide delivery systems, aiming to overcome the traditional reliance on injections for chronic metabolic conditions. Developers are incorporating advanced permeation enhancers and stabilizing technologies to improve the bioavailability of oral therapeutics, thereby addressing patient adherence challenges. This move towards non-invasive administration is supported by clinical successes in obesity management, such as Viking Therapeutics' August 2025 Phase 2 VENTURE trial, where oral VK2735 achieved up to 12.2% weight loss, demonstrating its competitive efficacy against injectable alternatives. Simultaneously, the development of Peptide Drug Conjugates (PDCs) for targeted oncology is expanding the market's therapeutic scope beyond metabolic and cardiovascular diseases. PDCs employ small peptide moieties to precisely deliver cytotoxic payloads, offering superior tissue penetration and faster clearance than larger antibody-drug conjugates. This approach is gaining traction for its potential to minimize systemic toxicity while maximizing potency against solid tumors, as evidenced by Bicycle Therapeutics' January 2025 Phase 1 Duravelo-1 trial, which reported a 65% overall response rate in metastatic urothelial cancer patients treated with zelenectide pevedotin.

Key Market Players

• Eli Lilly and Company
• Novo Nordisk A/S
• Sanofi S.A.
• Pfizer Inc.
• Takeda Pharmaceutical Co Ltd.
• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Biofer SpA
• Cipla Limited
• Aspen Pharmacare Holdings Limited

Report Scope

In this report, the Global Peptides and Heparin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptides and Heparin Market, By Type

• Peptides
• Heparin

Peptides and Heparin Market, By Application

• Oncology
• Metabolic Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Anticoagulation Therapy
• Others

Peptides and Heparin Market, By Route of Administration

• Injectable
• Oral
• Others

Peptides and Heparin Market, By End User

• Hospitals and Clinics
• Research Institutes and Laboratories
• Pharmaceutical and Biotechnology Companies
• Others

Peptides and Heparin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptides and Heparin Market.

Available Customizations:

Global Peptides and Heparin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptides and Heparin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Peptides, Heparin)
  • 5.2.2. By Application (Oncology, Metabolic Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Anticoagulation Therapy, Others)
  • 5.2.3. By Route of Administration (Injectable, Oral, Others)
  • 5.2.4. By End User (Hospitals and Clinics, Research Institutes and Laboratories, Pharmaceutical and Biotechnology Companies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Peptides and Heparin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Peptides and Heparin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Peptides and Heparin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Peptides and Heparin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Peptides and Heparin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Peptides and Heparin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. France Peptides and Heparin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Peptides and Heparin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Peptides and Heparin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Peptides and Heparin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia Pacific Peptides and Heparin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Peptides and Heparin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Peptides and Heparin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Peptides and Heparin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Peptides and Heparin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Peptides and Heparin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. Middle East & Africa Peptides and Heparin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Peptides and Heparin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Peptides and Heparin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Peptides and Heparin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Peptides and Heparin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Peptides and Heparin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Peptides and Heparin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Peptides and Heparin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Peptides and Heparin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eli Lilly and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novo Nordisk A/S
• 15.3. Sanofi S.A.
• 15.4. Pfizer Inc.
• 15.5. Takeda Pharmaceutical Co Ltd.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Abbott Laboratories
• 15.8. Biofer SpA
• 15.9. Cipla Limited
• 15.10. Aspen Pharmacare Holdings Limited

16. Strategic Recommendations

17. About Us & Disclaimer